title: [Pulmonary artery pressure measurement for assessment of bioavailability of isosorbide dinitrate and pentaerythritol tetranitrate (author's transl)].
abstract: In a double-blind cross-over study with 9 patients suffering from ischemic cardiomyopathy with cardiac failure, the effect of 3 different drug preparations on pulmonary artery pressure (PA-pressure) was studied. Iso-Ameritrat is a new drug-combination consisting of a sweet-tasting wrap containing 2.5 mg Isosorbide Dinitrate (ISDN) and of a bitter-tasting core containing 10 mg Pentaerythritol Tetranitrate (PETN) and 200 mg Meprobamate. A statistically significant decrease of PA-pressure values could be observed already 3 minutes after administration of Iso-Ameritrat. Within the next minutes this decrease even augmented and lasted over the whole period of measurement (30 minutes). After administration of the second drug preparation (Ameritrat), containing 10 mg PETN and 200 mg Meprobamate in the core, but not any nitrate in the wrap a slight but also statistically significant decrease of PA-pressure values could be documented. Therefore a sublingual resorption of PETN can be assumed. The precise beginning of the effect of PETN couldn't be assured, but it must be within 5 minutes. A thir preparation, containing only 200 mg Meprobamate in the bitter tasting core caused no significant decrease of PA-pressure values.
mesh_terms: D000328:Adult; D001682:Biological Availability; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007548:Isosorbide Dinitrate / Q000378:metabolism*; D008297:Male; D008620:Meprobamate / Q000494:pharmacology; D008875:Middle Aged; D010417:Pentaerythritol Tetranitrate / Q000378:metabolism*; D011651:Pulmonary Artery / Q000502:physiology*; D011652:Pulmonary Circulation / Q000187:drug effects*
chemical_list: D010417:Pentaerythritol Tetranitrate; D008620:Meprobamate; D007548:Isosorbide Dinitrate
vernacular_title: Pulmonalarteriendruckmessung zum Nachweis der Bioverfügbarkeit von Isosorbiddinitrat und Pentaerythroltetranitrat.